Acumen Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$105MTTM through 30 Jun 2026
Free Cash Flow -$91.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-172.3%ROE
-98.8%ROA
Balance Sheet Health
Debt / Equity0.44x
Current Ratio4.07x
Net Debt-$85.6Mnet cash position
Cash & Equivalents$59.4M
Quality Metrics
Altman Z-Score-6.36
Piotroski F-Score2 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$1.64TTMFY2025: $-2.00
Dividend
No dividend
Capital Allocation
R&D Spend$86.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Alzheimer's Disease Therapeutics | $0 | 0.0% | View detailsTopline results for ALTITUDE-AD are expected in late 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.